NCT03509844 is a NA clinical trial of Psychotherapy in Post-Traumatic Stress Disorder, sponsored by Modum Bad.

Who is sponsoring NCT03509844?

NCT03509844 is sponsored by Modum Bad.

What drugs are being tested in NCT03509844?

Interventions in NCT03509844: Psychotherapy.

What condition does NCT03509844 study?

NCT03509844 studies Post-Traumatic Stress Disorder.

Is NCT03509844 still recruiting?

NCT03509844 is currently completed. Last updated 30 March 2023.

Last reviewed 2023-03-30 · How we verify

NCT03509844

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Modum Bad Complex Posttraumatic Stress Disorder Study

Completed NA Last updated 30 March 2023

What this trial tests

NA trial testing Psychotherapy in Post-Traumatic Stress Disorder in 96 participants. Completed in 30 October 2021.

Timeline

20 September 2017

Primary endpoint
30 October 2021

30 October 2021

Quick facts

Lead sponsor	Modum Bad
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	96
Start date	20 September 2017
Primary completion	30 October 2021
Estimated completion	30 October 2021
Sites	1 location across Norway

Drugs / interventions tested

Psychotherapy

Conditions studied

Post-Traumatic Stress Disorder — all drugs for Post-Traumatic Stress Disorder →

Sponsor

Modum Bad

Who can join

Adults 18 to 65, any sex, with Post-Traumatic Stress Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study compares three established, manual based psychotherapies for Complex Post-traumatic Stress disorder (CPTSD) in patients with childhood trauma (e.g. sexual abuse, violence). The primary aim of the study is to compare phase-oriented treatment (Stabilization + Exposure) with two non-phased treatments, Exposure and Stabilization.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Predicting treatment outcome for complex posttraumatic stress disorder using the personalized advantage index.
Frost K, Hoeboer CM, Hoffart A, Sele P. · · 2025 · cited 1× · PMID 40302538 · DOI 10.1080/20008066.2025.2484060

Verify or expand the search:

Other trials of Psychotherapy

Trials testing the same drug.

NCT06827054 — Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids · Phase 2 · not yet recruiting
NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
NCT07507370 — CARED : A Novel Rapid Treatment Paradigm for Depression · NA · not yet recruiting
NCT07250893 — Resolving Early Life Stress: Psychotherapy Outcomes and Neurobiology in Complex Depression · NA · recruiting
NCT06353282 — MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents · Phase 2 · withdrawn

Other Modum Bad trials

Trials by the same sponsor.

NCT07432646 — "Finding Solid Ground" in Inpatient Treatment for Dissociative Disorder Patients Followed by Transition to Outpatient Tr · completed
NCT04444713 — Do Network Centrality Predict Overall Depression Symptom Reduction With Lifting of Social Distancing Protocols? · unknown
NCT04444115 — Loneliness During Strict and Lifted Social Distancing Protocols Against the COVID-19 Pandemic · unknown
NCT04365881 — Loneliness During the NPIs for the COVID-19 Pandemic in Norway: Risk Factors and Associations With Psychopathology · completed
NCT05993468 — A Pilot Study of a Trauma-Sensitive Mindfulness and Compassion Intervention · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03509844 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Modum Bad
Last refreshed: 30 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03509844.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing